Results 191 to 200 of about 32,890 (266)

Psoriasis [PDF]

, 2016
Elder, James T., Finlay, Andrew Y., Gladman, Dafna D., Goldminz, Ari M., Gottlieb, Alice B., Greb, Jacqueline E., Lebwohl, Mark G., Mehta, Nehal N., Wu, Jashin J.   +8 more
core   +1 more source

Ustekinumab Intravenous Reinduction after Secondary Loss of Response in Patients with Crohn's Disease. [PDF]

Inflamm Bowel Dis
Schreiber S, Lee SD, van der Woude CJ, Marín-Jiménez I, Wolf DC, Schnoy E, Salzberg B, Busse C, Nazar M, Ma T, Borghorst S, Gasink C, Baker T, Godwin B, Adedokun OJ, Feagan BG, POWER Study Group.   +16 more
europepmc   +1 more source

Advanced Medical Therapies for Perianal Fistulizing Crohn's Disease: A Systematic Review of Clinical, Radiological, Surgical, and Composite Outcomes. [PDF]

Pharmaceuticals (Basel)
Jamal F, Segun-Omosehin T, Viggiano T, Khan H, Gonzalez AJ, Thomas G, Elmasry S, Malik TA.   +7 more
europepmc   +1 more source

Quantification of visceral adipose tissue volume predicts both short-term and long-term transmural healing in patients with Crohn's disease receiving Ustekinumab. [PDF]

Ther Adv Gastroenterol
Wu X, Fan C, Duan X, Feng Z, Li X, Chen M, Wang Y, Zheng Q, Mao R.   +8 more
europepmc   +1 more source

Real-Life Use of Subcutaneous Biologicals and JAK Inhibitors in IBD Maintenance Therapy: Treatment Continuation, Switching Patterns, and Concomitant Medications. [PDF]

Clin Exp Gastroenterol
Koivusalo M, Jokelainen J, Huhtinen A, Kovac B, Silvola S, Torvinen S, Ylisaukko-Oja T, Arkkila P.   +7 more
europepmc   +1 more source

Retrospective Validation of Clinical Decision Support Tools for Predicting Effectiveness Outcomes in Inflammatory Bowel Disease Patients Treated with Vedolizumab. [PDF]

Pharmaceutics
de Klaver PAG, van Woerkens AMH, D'Agnolo HMA, Pierik MJ, Derijks LJJ.   +4 more
europepmc   +1 more source

Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. [PDF]

World J Gastroenterol
Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL.   +8 more
europepmc   +1 more source

Comparative Risk of Serious Infections Associated With Treatment of Inflammatory Bowel Disease. [PDF]

Inflamm Bowel Dis
Khan N, Sundararajan R, Patel D, Patel M, Bahirwani J, Mahmud N.   +5 more
europepmc   +1 more source

Effect of combined ustekinumab and partial enteral nutrition on clinical and nutritional outcomes in Crohn's disease. [PDF]

Medicine (Baltimore)
Wang S, Yang Y, Hu X, Liu P, Xu W, Zhou Y, Lin P, Yuan K, Lin T, Ding B.   +9 more
europepmc   +1 more source

Risankizumab is effective following ustekinumab failure in Crohn's disease: A real-world study from a tertiary center. [PDF]

World J Gastrointest Pharmacol Ther
Colwill M, Padley J, Qazi U, Mehta S, Donovan F, Alves AM, Pollok R, Patel K, Dawson P, Honap S, Poullis A.   +10 more
europepmc   +1 more source